Rosacea: Treating the Vascular–Inflammatory Overlap

Rosacea is not acne — the diagnosis is the treatment

One word settles most of it: comedones. Acne begins in the pore — a plugged follicle (the comedone) that Cutibacterium acnes then inflames. Rosacea has no comedones; the pore is not the problem. Its stage is the central face — cheeks, nose, chin, forehead — and its features come in a mix: transient flushing that overreacts to triggers, persistent background erythema (redness that no longer fades), inflammatory papules and pustules, visible telangiectasia (dilated surface vessels), phymatous change (thickened, bulbous skin, classically of the nose), and ocular rosacea (dry, gritty, inflamed eyes). Because the biology is vascular and inflammatory rather than a blocked, oily pore, the acne toolkit misfires: harsh benzoyl peroxide and scrubs tend to irritate rosacea, and there is nothing to "unclog." Naming the disease correctly is the first therapeutic act.

Treat the phenotype, not the label

Modern practice has dropped the old habit of forcing every patient into one "subtype" and instead treats each feature that is present. This matters because the features answer to completely different drugs. Redness and flushing are a vascular problem — they respond to vasoconstrictors and trigger control, and barely at all to anti-inflammatory creams. Papules and pustules are an inflammatory problem — they respond to anti-inflammatory topicals and to anti-inflammatory oral therapy. Fixed telangiectasia and phyma are structural — no cream reverses a dilated vessel or a thickened nose, so they belong to lasers and surgery. Read the face, list what is actually there, and match each finding to its mechanism. A patient with both bright persistent redness and crops of pustules genuinely needs two different agents working on two different pathways.

The redness: topical vasoconstrictors and trigger control

If the problem is a dilated vessel, the answer is a drug that tightens it. For persistent erythema and flushing, two topical adrenergic agonists constrict the superficial facial vessels directly. Brimonidine is an alpha-2 adrenergic agonist; oxymetazoline is an alpha-1 agonist — the same alpha-adrenergic vasoconstriction covered in the Autonomic Nervous System chapter, here applied as a once-daily gel or cream. Both fade the redness for a matter of hours, then wash out; they are a cosmetic on-off switch, not a cure, and the underlying tendency is unchanged. The crucial caveat, and a favourite exam trap, is rebound erythema: as brimonidine wears off, some patients flush worse than their baseline, occasionally with a worsening that discourages them from the drug entirely. Counsel this before prescribing. Alongside the drugs sits the least glamorous but most durable measure — trigger avoidance: sun (a daily broad-spectrum sunscreen is foundational), heat, hot drinks, spicy food, and alcohol are the classic provocateurs, and identifying a patient's own list often does more than any tube. For flushing driven by autonomic surges — the blush that overwhelms — a systemic beta-blocker such as carvedilol or propranolol can blunt the response, again borrowing directly from the adrenergic pharmacology of the Autonomic chapter.

The bumps: anti-inflammatory topicals

For the inflammatory papules and pustules, three topicals form the backbone, and their names are misleading because their value in rosacea is anti-inflammatory rather than antibacterial. Topical metronidazole — an old antimicrobial elsewhere — calms rosacea by damping inflammatory and reactive-oxygen pathways in the skin, not by killing a causative bug; it is a gentle, well-tolerated first-line. Azelaic acid is both anti-inflammatory and normalizes the disordered skin around the follicle, and it doubles as a mild option many patients tolerate well. The most mechanistically interesting is topical ivermectin: it is simultaneously anti-inflammatory and anti-parasitic against Demodex, the follicular mite implicated in rosacea's inflammation (its antiparasitic action links to the ivermectin pharmacology in the Antimicrobials chapter, and metronidazole appears there too). Ivermectin often produces the cleanest results in papulopustular disease, which fits the idea that reducing the Demodex load removes an inflammatory stimulus.

Oral therapy: sub-antimicrobial doxycycline and low-dose isotretinoin

The most examined single fact in rosacea: the dose that is deliberately too low to kill bacteria. When topicals are not enough, the workhorse oral drug is doxycycline given at a sub-antimicrobial dose. This is the key exam point: a modified-release low dose is used precisely because it is below the threshold that suppresses bacteria, yet still delivers doxycycline's anti-inflammatory effects — inhibition of matrix metalloproteinases, neutrophil chemotaxis, and pro-inflammatory cytokines. Because it is not acting as an antibiotic, it does not exert the selection pressure that breeds resistance, which is why it is preferred over old-fashioned full antibacterial dosing. This is the same sub-antimicrobial-dose doxycycline concept introduced in the Systemic Acne chapter, reused here for a disease that is inflammatory, not infective. For papulopustular rosacea that resists topicals and doxycycline, low-dose oral isotretinoin is the next step — the same retinoid detailed in the Isotretinoin chapter, but used at gentler doses than in nodulocystic acne. It shrinks sebaceous activity and calms inflammation, and it carries the identical non-negotiable safeguards: it is a potent teratogen requiring strict pregnancy prevention, with monitoring of lipids and liver enzymes. Rosacea does not license any shortcut around isotretinoin's rules.

The eye, the structure, and the mite underneath

Ocular rosacea is quietly common and easy to miss: burning, grittiness, dryness, red lid margins, recurrent styes, and blepharitis, sometimes without much facial redness at all. Its mainstay is unglamorous — lid hygiene (warm compresses and lid cleansing) and ocular lubricants — backed, when inflammation is significant, by the same oral tetracyclines (doxycycline) used for the skin, again for their anti-inflammatory action; significant eye disease warrants ophthalmology input. Two features, though, sit outside pharmacology entirely. Fixed telangiectasia — established, permanently dilated surface vessels — will not respond to any cream or tablet; they are erased with vascular laser or intense pulsed light. Phymatous change such as rhinophyma, the thickened bulbous nose, is a structural remodelling that likewise needs ablative laser or surgical debulking, not a drug. It is worth stating plainly to patients: some parts of rosacea are treated by pharmacology and some are not. Underneath all of it lies the disease's biology — an over-reactive innate immune response (with elevated cathelicidin peptides), neurovascular dysregulation of facial vessels, and a heavier-than-normal load of Demodex mites and their associated microbiome. That Demodex–microbiome axis is exactly why an anti-parasitic like ivermectin earns a place in a disease that, on the surface, looks purely inflammatory.